Severe fever with thrombocytopenia syndrome (SFTS) is an emerging infectious disease with a high case fatality rate of up to 30% (1-3). The causative agent is a novel phlebovirus of the Bunyaviridae family, namely, SFTS virus (SFTSV), which was identified first in China and subsequently was found in South Korea (4, 5) and Japan (6). Recently, another phlebovirus genetically closely related to SFTSV was isolated in the United States (7). Emerging bunyavirus infection has become a substantial threat to public health; however, the pathogenesis is largely unknown, and there are no vaccines or specific antivirals available. The SFTSV genome consists of three single-stranded RNA segments. The large (L) and medium (M) segments are of negative polarity and encode the RNA-dependent RNA polymerase and the glycoprotein precursor, respectively, while the small segment (S) encodes the nucleoprotein (NP) and the nonstructural protein (NSs) by an ambisense strategy. Although little is known on SFTSV-host interactions, studies have suggested that the NSs protein is implicated in viral suppression of host antiviral innate immunity; thus, it likely is contributing to viral pathogenesis (8-10).Antiviral innate immune response is initiated through the recognition of virus infection by cellular pattern recognition receptors (PRRs), such as transmembrane toll-like receptor 3 (TLR3) and cytosolic RIG-I-like receptors RIG-I and MDA5 (11). Upon recognition, PRRs trigger the signaling cascades that lead to the induction of type I interferons (IFNs) through the activation of transcription factors, such as interferon regulatory factors (IRFs) 3 and 7 and NF-B. The newly synthesized and secreted type I IFNs bind to their receptors on the cell surface and result in the phosphorylation of signal transducer and activator of transcription 2 (STAT2) and 1 (STAT1), transcription factors that are the key components of type I IFN signaling pathway, by Janus kinases (JAKs). The phosphorylated STATs then heterodimerize and as-